These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173 [Abstract] [Full Text] [Related]
3. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis. Lacaze-Masmonteil T, Rozé JC, Fauroux B, French Pediatricians' Group of Sunagis Patients' Name-Based Programs. Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846 [Abstract] [Full Text] [Related]
4. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile? Hashmi NA, Cosgrove JF, MacMahon P. Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917 [Abstract] [Full Text] [Related]
5. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, IRIS Study Group. Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376 [Abstract] [Full Text] [Related]
6. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Romero JR. Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452 [Abstract] [Full Text] [Related]
13. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics; 1997 Jan; 99(1):93-9. PubMed ID: 8989345 [Abstract] [Full Text] [Related]
14. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia. Grimaldi M, Gouyon B, Michaut F, Huet F, Gouyon JB, Burgundy Perinatal Network. Pediatr Infect Dis J; 2004 Dec; 23(12):1081-5. PubMed ID: 15626942 [Abstract] [Full Text] [Related]
15. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627 [Abstract] [Full Text] [Related]
16. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group. Carbonell-Estrany X. Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453 [Abstract] [Full Text] [Related]